Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2: GLP-1 medications are contraindicated for these conditions
Pasternak B et al
Adults with obesity, defined as having a body mass index (BMI) of 30 kg/m or higher, or overweight, defined as having a BMI of 27 kg/m or greater with at least one weight-related condition, were eligible to participate
Prior to SELECT, no weightmanagement medication carried a specific indication to lower MACE risk in patients with overweight or obesity but without diabetes
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA, SUMMIT Trial Study Group
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the active pharmaceutical ingredient in widely prescribed treatments such as Ozempic, Rybelsus, and Wegovy
US$ 20.40
US$ 21.64
US$ 21.46
US$ 24.38
US$ 29.29
